|
10th Anniversary Conference Of The British HIV Association [BHIVA]15 – 17 April 2004, City Hall, Cardiff, UK |
[AUTHOR(S):] Y Gilleece, MR Nelson, A Clarke, M Fisher, M Bower, M Atkins, BG Gazzard
Chelsea and Westminster Hospital, London, UK
BHIVA Conf 2004 Apr 15-17;10:O19
AIM: To investigate the use of tenofovir in HBV/HIV co-infected individuals.
METHODS: An open-label study of HBV/HIV co-infected individuals receiving tenofovir.
RESULTS: 40 co-infected HBeAg +ve individuals were identified, 39 male and one female, with a median age of 37.5 years. They received tenofovir at 245 mg once a day as part of, or in addition to, their combination antiretroviral therapy. 31 were lamivudine-experienced, with a median exposure of 72 weeks (range 6–270). 60% of those who underwent HBV DNA polymerase sequencing had a mutation in the YMDD motif. The median CD4 count rose from 271 (baseline) to 386 (48 weeks) and 488 cells/µl at 96 weeks. Similarly, the CD4% rose from baseline to 96 weeks (19.2% to 24% to 22.5%). The median HBV DNA level fell from 250 × 106 to <10,000 copies/ml at 96 weeks. 25/40 (63%) had an undetectable HBV by 48 weeks. 14/14 (100%) who reached 96 weeks had an undetectable HBV DNA level. Eight individuals became HBeAg-ve between 36 and 96 weeks, and six seroconverted to HBeAb+ve. Three of these six had lamivudineresistant mutations at baseline. All eight individuals remained HBsAg+ve.
CONCLUSION: Tenofovir is effective against HBV in HIV co-infected lamivudine-experienced individuals.
PRESENTING AUTHOR: Y Gilleece
040415
O19
Copyright © 2004 - British HIV Association (BHIVA) Reproduction of this abstract (other than one copy for personal reference) must be cleared through the BHIVA Organising Secretariat 1 Mountview Court, 310 Friern Barnet Lane, London N20 0LD